Do analysts prefer KPRX or VERU?

Veru has a consensus price target of $24.50, indicating a potential upside of 914.49%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is KPRX or VERU more profitable?

Veru's return on equity of -47.58% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Veru N/A -47.58% -35.83%

Does the media prefer KPRX or VERU?

In the previous week, Veru had 2 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 6 mentions for Veru and 4 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.63 beat Veru's score of 0.16 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer KPRX or IXHL?

Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 434.12%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is KPRX or IXHL more profitable?

Kiora Pharmaceuticals' return on equity of -63.38% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Incannex Healthcare N/A -81.01% -76.11%

Does the media refer more to KPRX or IXHL?

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 2 mentions for Incannex Healthcare. Kiora Pharmaceuticals' average media sentiment score of 0.63 equaled Incannex Healthcare'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incannex Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VIRI or KPRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VIRI or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -63.38% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Kiora Pharmaceuticals N/A -63.38% -44.33%

Do analysts prefer KPRX or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 618.75%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Do analysts recommend FLNA or KPRX?

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 555.22%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FLNA or KPRX more profitable?

Cassava Sciences' return on equity of -58.78% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Kiora Pharmaceuticals N/A -63.38% -44.33%

Kiora Pharmaceuticals (KPRX) Competitors

$2.65 +0.00 (+0.15%)

As of 10:51 AM Eastern

Compare

KPRX vs. VERU, IXHL, VIRI, KPTI, and FLNA

Should you buy Kiora Pharmaceuticals stock or one of its competitors? Kiora Pharmaceuticals's main competitors and comparable companies include Veru (VERU), Incannex Healthcare (IXHL), Virios Therapeutics (VIRI), Karyopharm Therapeutics (KPTI), and Cassava Sciences (FLNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Kiora Pharmaceuticals compare to Veru?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Veru's return on equity of -47.58% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Veru	N/A	-47.58%	-35.83%

Kiora Pharmaceuticals has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market. Comparatively, Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

Kiora Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
Veru	$16.89M	2.44	-$22.73M	-$0.69	N/A

Veru has a consensus price target of $24.50, indicating a potential upside of 914.49%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Veru had 2 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 6 mentions for Veru and 4 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.63 beat Veru's score of 0.16 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Veru beats Kiora Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Incannex Healthcare?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Kiora Pharmaceuticals has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -63.38% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Incannex Healthcare	N/A	-81.01%	-76.11%

Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 434.12%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiora Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
Incannex Healthcare	$90K	448.21	-$46.88M	-$1.55	N/A

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 2 mentions for Incannex Healthcare. Kiora Pharmaceuticals' average media sentiment score of 0.63 equaled Incannex Healthcare'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incannex Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiora Pharmaceuticals and Incannex Healthcare tied by winning 7 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kiora Pharmaceuticals' return on equity of -63.38% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Virios Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market.

In the previous week, Kiora Pharmaceuticals had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 0 mentions for Virios Therapeutics. Kiora Pharmaceuticals' average media sentiment score of 0.63 beat Virios Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Kiora Pharmaceuticals	Positive

Summary

Kiora Pharmaceuticals beats Virios Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Kiora Pharmaceuticals had 3 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 0.63 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Positive
Karyopharm Therapeutics	Very Positive

Kiora Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Kiora Pharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
Karyopharm Therapeutics	$146.07M	0.25	-$196.04M	-$13.09	N/A

Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 618.75%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Kiora Pharmaceuticals has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Karyopharm Therapeutics beats Kiora Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

In the previous week, Kiora Pharmaceuticals had 3 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Kiora Pharmaceuticals and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 0.63 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Very Positive
Kiora Pharmaceuticals	Positive

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 555.22%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cassava Sciences' return on equity of -58.78% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Cassava Sciences has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market.

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kiora Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A

Summary

Cassava Sciences beats Kiora Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.73M	$12.55B	$7.22B	$12.73B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-1.06	797.26	274.90	25.33
Price / Sales	0.73	756.47	646.10	90.47
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.61	10.41	10.39	6.23
Net Income	-$10.84M	$2.84B	$3.50B	$358.31M
7 Day Performance	4.08%	-3.41%	-2.43%	-1.45%
1 Month Performance	4.08%	0.67%	0.08%	-2.79%
1 Year Performance	0.53%	3.83%	23.83%	8.30%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	0.6864 of 5 stars	$2.65 +0.2%	N/A	+0.4%	$11.73M	$16.02M	N/A	10	News Coverage Gap Down
VERU Veru	2.7055 of 5 stars	$2.48 -3.9%	$24.50 +887.9%	-29.3%	$43.99M	N/A	N/A	230
IXHL Incannex Healthcare	2.0201 of 5 stars	$3.23 -4.2%	$18.00 +457.3%	-80.2%	$40.32M	$90K	N/A	3
VIRI Virios Therapeutics	N/A	$2.04 -10.9%	N/A	-60.3%	$39.29M	N/A	N/A	5
KPTI Karyopharm Therapeutics	3.2302 of 5 stars	$1.69 -1.7%	$11.50 +580.5%	-75.0%	$39.01M	$146.07M	N/A	380	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. VERU, IXHL, VIRI, KPTI, and FLNA

How does Kiora Pharmaceuticals compare to Veru?

Summary

How does Kiora Pharmaceuticals compare to Incannex Healthcare?

Summary

How does Kiora Pharmaceuticals compare to Virios Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. VERU, IXHL, VIRI, KPTI, and FLNA

How does Kiora Pharmaceuticals compare to Veru?

Is KPRX or VERU more profitable?

Which has more volatility & risk, KPRX or VERU?

Which has higher valuation and earnings, KPRX or VERU?

Do analysts prefer KPRX or VERU?

Does the media prefer KPRX or VERU?

Do insiders & institutionals believe in KPRX or VERU?

Summary

How does Kiora Pharmaceuticals compare to Incannex Healthcare?

Which has more risk & volatility, KPRX or IXHL?

Is KPRX or IXHL more profitable?

Do analysts prefer KPRX or IXHL?

Which has higher earnings & valuation, KPRX or IXHL?

Do institutionals & insiders hold more shares of KPRX or IXHL?

Does the media refer more to KPRX or IXHL?

Summary

How does Kiora Pharmaceuticals compare to Virios Therapeutics?

Do analysts recommend VIRI or KPRX?

Is VIRI or KPRX more profitable?

Which has higher valuation and earnings, VIRI or KPRX?

Do institutionals and insiders hold more shares of VIRI or KPRX?

Which has more risk & volatility, VIRI or KPRX?

Does the media favor VIRI or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Does the media refer more to KPRX or KPTI?

Is KPRX or KPTI more profitable?

Which has better valuation & earnings, KPRX or KPTI?

Do analysts prefer KPRX or KPTI?

Which has more volatility and risk, KPRX or KPTI?

Do institutionals & insiders have more ownership in KPRX or KPTI?

Summary

How does Kiora Pharmaceuticals compare to Cassava Sciences?

Does the media prefer FLNA or KPRX?

Do analysts recommend FLNA or KPRX?

Is FLNA or KPRX more profitable?

Which has more volatility & risk, FLNA or KPRX?

Do institutionals & insiders believe in FLNA or KPRX?

Which has better earnings & valuation, FLNA or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools